Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 2027-2036

  Jiménez Ruiz, Carlos A ^a   Solano Reina, Segismundo ^b   Signes Costa, Jaime ^c   de Higes Martinez, Eva ^d   Granda Orive, José I ^e   Lorza Blasco, José J ^f   Riesco Miranda, Juan A ^g   Altet Gomez, Neus ^h   Barrueco, Miguel ⁱ   Oyagüez, Itziar ^j   Rejas, Javier ^k  

^a Specialised Tobacco Unit Community of Madrid ^*  (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f Instituto de Investigación Sanitaria de Navarra   (Spain)

^g San Pedro de Alcántara Hospital   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

^k Department of Pharmacoeconomics and Health Outcomes ^*  (Spain)

more..

Author keywords

Budgetary impact; COPD; Health service; Pharmacotherapy; Smoking cessation

Indexed keywords

AMFEBUTAMONE; VARENICLINE; NICOTINE GUM;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COST BENEFIT ANALYSIS; FEMALE; FOLLOW UP; FUNDING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PREVALENCE; REIMBURSEMENT; SENSITIVITY ANALYSIS; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SPAIN; TREATMENT DURATION; COMPLICATION; DRUG THERAPY; ECONOMICS; EPIDEMIOLOGY; MARKOV CHAIN; MIDDLE AGED; SMOKING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BUPROPION; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; SMOKING CESSATION; SPAIN; TOBACCO USE CESSATION PRODUCTS; VARENICLINE;

EID: 84942751017     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S87597     Document Type: Article

References (41)

1. World Health Organization. Geneva; 2014. Available from: http://www.who.int/tobacco/health_priority/en/index.html. Accessed July 21, 2014.
2. Banegas JR, Díez-Gañán L, Bañuelos-Marco B, et al. Smoking-attributable deaths in Spain, 2006. Med Clin (Bare). 2011;136:97-102.
3. Fiore MC, Jaén CR, Baker TB. Treating Tobaeeo Use and Dependence: 2008 Update. Clinical Practice Guideline; 2013. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. Available from: http://www.ncbi.nlm.nih.gov/books/NBK63952/. Accessed September 27, 2013.
4. Rennard SI, Daughton DM. Smoking cessation. Clin Chest Med. 2014;35:165-176.
5. Rigotti NA. Smoking cessation in patients -with respiratory disease: existing treatments and future directions. LancetRespirMed. 2013;1:241-250.
6. Lock K, Wilson K, Murphy D, Riesco JA. A cost-effectiveness model of smoking cessation based on a randomized controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2011;12:2613-2626.
7. Jiménez-Ruiz CA, Riesco Miranda JA, Altet Gómez N, et al; Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Treatment of smoking in smokers with chronic obstructive pulmonary disease. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch Bronconeumol. 2013;49:354-363.
8. SEMERGEN. Consenso para la prevención y terapia de la enfermedad tabáquica [Consensus for prevention and therapy of smoking]; 2007. Available from: http://www.semergen.es. Accessed June 26, 2014.
9. González-Enríquez J, Salvador-Llivina T, López-Nicolás A, et al. The effects of implementing a smoking cessation intervention in Spain on morbidity, mortality and health care costs. Gac Sanit. 2002;16:308-317.
10. Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Ibañez-Nolla J. The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice. Lung. 2014;192:505-518.
11. Jiménez-Ruiz CA, Riesco Miranda JA, Ramos Pinedo A, et al. Recommendations for pharmacological tobacco cessation treatments: proposals for financing. Arch Bronconeumol. 2008;44:213-219.
12. López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ. 2010;11:513-520.
13. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17: 5-14.
14. Sicras-Mainar A, Navarro Artieda R, Díaz Cerezo S, Martí-Sanchéz B, Sanz De Burgoa V. Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care. Aten Primaria. 2011;43:482-489.
15. Soriano JB, Ancochea J, Miravitlles M, et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. Eur Respir J. 2010;36:758-765.
16. National Institute of Statistics (INE) of Spain. Proyecciones de la población española for 2013 [Spanish population projections for 2013]; 2013. Available from: http://www.ine.es. Accessed September 27, 2013.
17. de Miguel Diez J, Carrasco Garrido P, García Carballo M, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008;3:701-712.
18. Comité Nacional para la Prevención del Tabaquismo; 2008 National Committee for Prevention of smoking: 2008. Available from: http://www.cnpt.es/listado-recursos.asp?id_categoria=23&id_subcategoria=-1&pagina=8. Accessed September 27, 2013.
19. Jiménez Ruiz CA, Fernando Masa J, Sobradillo V, et al. Prevalence of and attitudes towards smoking in a population over 40 years of age. Arch Bronconeumol. 2000;36:241-244.
20. de Lucas Ramos P, Álvaro Alvarez D. Actualizaciones en la EPOC 2010 [Update for COPD 2010]. Monografías NEUMOMADRID, Vol. 15; 2010. Available from: http://www.neumomadrid.org/des-cargas/monog_neumomadrid_xv.pdf. Accessed September 27, 2013.
21. Getsios D, Marton JP, Revankar N, et al. Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions. Pharmacoeconomics. 2013;31:767-780.
22. Krall EA, Garvey AJ, Garcia RI. Smoking relapses after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res. 2002;4:95-100.
23. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet. 2001;357:1571-1575.
24. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139:591-599.
25. T0nnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest. 2006;130:334-342.
26. Zhu SH, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quit line for smokers. N Engl J Med. 2002; 347:1087-1093.
27. Drug Catalogue of the Consejo General de Colegios de Farmacéuticos. Bot Plus Web; 2013 Drug Catalogue of the General Council of Official Colleges of Pharmacists. Available from: http://www.portalfarma.com. Accessed September 27, 2013.
28. Royal Decree-Law (RD). RealDecreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. BOE [Spain’s Official Government Gazette] de 24 de Mayo 2010:126; 2010. Available from: www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf. Accessed June 25, 2014.
29. Wetter DW, Cofta-Gunn L, Fouladi RT, Cinciripini PM, Sui D, Gritz ER. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med. 2004;39:1156-1163.
30. Jiménez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A, Mayayo Ulibarri M, Cristobal Fernández M, Lopez Gonzalez G. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res. 2012;14:1035-1039.
31. Brosa M, Gisbert R, Rodríguez JM, Soto J. Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario [Principles, methods and applications for budgetary impact analysis for health interventions]. Pharmacoecon Span Res Artic. 2005;2:64-78.
32. Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmaco-therapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control. 2006;15:152-159.
33. Song F, Raftery J, Aveyard P, Hyde C, Barton P, Woolacott N. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making. 2002;22(5 Suppl):S26-S37.
34. Fernández de Bobadilla Osorio J, Sánchez-Maestre C, BrosaRiestra M, Arroyo O, Sanz De Burgoa V, Wilson K. Cost effectiveness analysis of varenicline (Champix) for the treatment of smoking in Spain. An Med Interna. 2008;25:342-348.
35. Antoñanzas F, Portillo F. Evaluación económica del empleo de terapias farmacológicas para la cesación en el hábito tabáquico [Economic evaluation of pharmacotherapies for smoking cessation]. Gac Sanit. 2003;17:393-403.
36. de Granda JI, Carrión F, Alonso S, et al; Area de Tabaquismo de la SEPAR. Tobacco addiction: care and services. Arch Bronconeumol. 2006; 42:600-604.
37. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease; 2010. Available from: http://www.goldcopd.org/. Accessed September 2013.
38. Menzin J, Lines LM, Marton J. Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right? Expert Rev Pharmacoecon Outcomes Res. 2009;9:257-264.
39. Warner KE, Mendez D, Smith DG. The financial implications of coverage of smoking cessation treatment by managed care organizations. Inquiry. 2004;41:57-69.
40. Tarifas de asistencia sanitaria ambulatoria de la Comunidad de Madrid (B.O.C.M. 215 de 10 de septiembre de 2013) Tariffs of healthy outpatient resources of Autonomous Community of Madrid; 2013. Available from: http://w3.bocm.es/boletin/CM_Orden_BOCM/2013/09/10/ BOCM-20130910-1.PDF. Accessed September 27, 2013.
41. Guía de deshabituación tabáquica del Instituto Catalán de la Salud; 2013 Guideline for smoking cessation of the Catalonia Institute of Health. Available from: http://www.ics.gencat.cat/3clics/main.php?page=GuiaPage&idGuia=1&lang=CAS. Accessed September 27, 2013.